Raquel Luque - Concepedia

Author

Raquel Luque

Hospital Universitario Virgen de las Nieves ORCID

Also Known As

María Luisa Limón, R Luque, R. Luque, R. Luque Caro, R. Morales, R.M. Luque, Raquel Luque, Raquel Luque Caro

Publications

986

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen de las Nieves Institut Català d'Oncologia Hospital Universitari Germans Trias i Pujol Fundación Hospital Provincial de Castellón Hospital Del Mar

About

Raquel Luque is an author at Hospital Universitario Virgen de las Nieves specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	362
2	Health Sciences	3	3	67
3	Cell Biology	3	3	197
4	Engineering	1	1	161
5	Biomedical Engineering	1	1	161

Raquel Luque

Publications

851

Citations

H-Index

Page 1

	Year	Citations
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications Raúl Ortíz, Gloria Perazzoli, Laura Cabeza, Current Neuropharmacology Nanotechnology AdvancesEngineeringBiomedical EngineeringHigh-grade GliomasGlioma	2020	161
Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá, Neuro-Oncology	2017	119
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01) Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez, Neuro-Oncology	2020	103
Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles Maria Adolfina Ruiz Martínez, José Manuel Entrena, Raquel Luque, International Journal of Nanomedicine	2015	70
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017) Maria Martinez‐García, Juan Álvarez‐Linera, Cristina Carrato, Clinical & Translational Oncology	2017	70
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, Annals of Oncology Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicine	2023	69
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial Carmen Balañá, R. de las Peñas, Juan Manuel Sepúlveda-Sánchez, Journal of Neuro-Oncology Neuro-oncologyGenom 009MedicineNeoadjuvant TreatmentNeurology	2016	55
Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients Anna Estival, Carolina Sanz, José Luis Ramírez, Scientific Reports	2019	39
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program Daniel Castellano, Luis Aparicio, Emilio Esteban, Expert Opinion on Drug Safety	2014	28
Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure Consolación Melguizo, José Prados, Raquel Luque, International Journal of Molecular Sciences Mrp3 Gene ExpressionCarboplatin ExposureCancer BiologyTumor BiologyDrug Resistance	2012	26

Page 1